04:48 PM EST, 11/17/2025 (MT Newswires) -- Enanta Pharmaceuticals ( ENTA ) reported a fiscal Q4 loss late Monday of $0.87 per diluted share, narrowing from a loss of $1.36 a year earlier.

Analysts polled by FactSet expected a loss of $1.03.

Revenue for the three months ended Sept. 30 was $15.1 million, up from $14.6 million a year earlier.

Analysts surveyed by FactSet expected $16 million.

Enanta said it believes its cash, cash equivalents, marketable securities, future royalty revenue and proceeds from its October public offering will be sufficient to support its business and development programs into fiscal 2029.

Shares of Enanta were down nearly 2% in after-hours trading.